PharmaTalkRadio

Bölümler

• 
  What’s Next in Immuno-Oncology - A Visionary Conversation with Dr Ira Mellman 01.09.2026 29dk

  This podcast features a fireside chat between Dr Ira Mellman, PICI and Dr Axel Hoos, Former CEO, Scorpion Therapeutics from the 2026 Immuno-Oncology 360° conference. Drawing on Dr Mellman’s extensive experience and current work at the Parker Institute for Cancer Immunotherapy, this conversation provides:Insight into the scientific and clinical trajectory of immuno-oncologyPerspectives on the evolving role of collaboration and innovative partnership models like PICIDiscussion of the key opportunities and challenges shaping IO innovation at scaleA visionary outlook on what the next chapter of immuno-oncology could look likeTo learn more about the IO360° Summit, please visit https://www.io360summit.com/
• 
  New Biotech-Academia Partnership Approaches to Empower the Drug Development Ecosystem 07.08.2026 25dk

  As alternative funding pathways decrease and fewer research grants are administered, the relationship between biotech and academia must shift in order to continue to achieve innovation and development. In this podcast, featuring a panel discussion from the 2026 Chief Medical Officer Summit 360°, CMOs and academics present on these shifts in the global clinical development ecosystem, and how academia and biotech can better partner to develop new therapies for patients, with specific examples.To learn more about the Chief Medical Officer Summit 360°, please visit CMOSummit360.com.
• 
  Developing a Global Clinical Trial Strategy for Emerging Biotechs 07.08.2026 29dk

  This podcast feature a panel discussion from the 2026 Chief Medical Officer Summit 360°, biotech CMOs and executives from CROs and consultancies. Together they discuss how small biotechs can accelerate clinical development with fit-for-purpose global clinical trial strategies. Specifically: The benefits and challenges of running clinical trials in different regionsWhen and at which phases to run clinical trials in different countriesBridging data for approval applicationsManaging global clinical trials in areas with different cultures and health systemsTo learn more about the Chief Medical Officer Summit 360°, please visit CMOSummit360.com.
• 
  How Pharma Teams Evaluate Biotech Companies for Partnerships and Acquisitions 07.08.2026 29dk

  This podcast features a panel discussion from the 2026 Chief Medical Officer Summit 360°, with biotech CMOs and representatives from pharma companies. Together, they address how interactions around partnerships or acquisitions differ from those of investment from biotech companies and how CMOs can support those conversations. This includes:How pharma companies analyze potential partnersWhat biotech companies can do to best partner with pharma How the CMO fits into various phases of transactionsAppreciating how different c-suite colleagues and direct reports experience these transactionsThe different pharma teams CMOs will interact withCommon challenges to partnerships and how to pre-empt themWhat happens after the acquisitionTo learn more about the Chief Medical Officer Summit 360°, please visit CMOSummit360.com.
• 
  What to Expect at Partnerships with Sites 2026 14.07.2026 5dk
• 
  Unlocking Unstructured Data with AI for Optimized Protocol Development 02.06.2026 24dk

  In this podcast, Mike Eckrote, SVP, Strategic Solutions at Advarra, talks about how artificial intelligence is being used to pull insights out of structured and unstructured data sources to help sponsors avoid protocol amendments and delays.  More specifically, Mike discusses:  How Advarra is leveraging past IRB data sources to identify common causes of site burden, study delays and amendments What questions sponsors should be asking of AI vendors, to pick the correct partner How sponsors have responded to the insights surfaced by this technology  Why sponsors must adapt to a flexibility mindset in order to truly make changes with downstream impact 
• 
  Bridging Access Gaps: Sponsor-Led Enablement of Research-Naïve Sites to Expand Patient Reach 08.05.2026 23dk

  Tapping into research-naïve sites offers a strategic opportunity to expand patient access. That’s exactly what Endo did when faced with challenges activating sites for their orthopedic study. This case study shares how Endo enabled a new site through hands-on mentorship, infrastructure support, and trust-building— resulting in sustainable partnerships and broader patient reach.How naïve sites can help address access and enrollment bottlenecksHow to support inexperienced sites with the right sponsor-led infrastructureWhat it takes to shift internal expectations and foster lasting site partnershipsSpeakers:Carrie Lewis Executive Director, Clinical Program Optimization, EndoSuzy Montayne Site Relationship Manager, EndoTerry Oehler, DPM Founder & CEO, Colorado Clinical Research
• 
  Building Trust-Driven Partnerships: AstraZeneca’s Concierge Approach to Accelerating Site Activation and Enrollment 08.05.2026 21dk

  AstraZeneca’s US Site Engagement Leads will share how they are reimagining sponsor-site relationships through a trust-first, high-engagement operating model that emphasizes flexibility, responsiveness, and co-creation. This session will showcase how their embedded approach to collaboration has enabled faster site activation, stronger recruitment performance, and improved data delivery—backed by real metrics and lessons learned from a three-year initiative. Key topics include:How continuous site feedback loops and flexibility with SOPs improved startup timelinesMetrics from a recent study showing impact: 30% faster budget negotiations, 27% reduced activation times, 68% of recruitment from 42% of sitesTools and tactics used to build consistency, transparency, and trust across studiesLessons learned and how the program has scaled globallySpeakers:Shannon Edwards Site Engagement Lead, AstraZenecaTina Nghiem Site Engagement Lead, AstraZeneca
• 
  Eli Lilly on Site Enablement: Co-Designing Solutions with Sites 08.05.2026 43dk

  A case study highlighting how Eli Lilly partnered with clinical sites to co-design practical, site-centric solutions that enhanced trial execution and operational efficiency.Fireside Guest: Shafaat Ali Khan Clinical Research Lead (CRL) Director – Investigator Engagement, Eli Lilly & CoModerator: Jyoti Angal, PhD Director, Clinical Research, Avera McKennan Hospital & University Health Center
• 
  What a Strategic Partnership Looks Like in Practice: Inside the Takeda–Basil Collaboration That Delivered Tenfold Enrollment 08.05.2026 20dk

  This case study highlights how Basil Clinical Research and Takeda’s first-time partnership became the top global recruiter, exceeding enrollment goals by tenfold through proactive assessments, early collaboration, and inclusive design. Learn how Takeda’s shift from transactional to strategic, long-term partnerships made this success possible.Identifying and partnering with highpotential sitesIncorporating site feedback and early collaboration to improve trial executionBuilding trust and fostering long-term site relationshipsKey actions that led to exceptional enrollment and trial efficiencySpeakers:Brandon Doyle, MBA Associate Director, Study Site Engagement, Takeda Mark Rapp, MD Principal Investigator, Basil Clinical Research
• 
  Using Digital Technologies to Enhance Patient Experience and Better Manage Supply Chain 05.05.2026 29dk

  In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts address: Integrating connectivity into drug delivery devices as a way to improve patient engagement and adherenceHow pharma can use drug delivery device data with predictive analytics to forecast demand and optimize productionEnabling patient-centric design and innovation by analyzing device usage dataTo learn more about the PODD Conference, please visit PODDConference.com.
• 
  Ensuring Sustainability Throughout Drug and Device Development 05.05.2026 28dk

  In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts address how the biopharma and drug delivery industries actively move to embed sustainability into core principles, products and processes. Specifically:How pharma and suppliers can improve sustainabilityCreating designs with lower carbon footprints relative to fabrication and materialsCircular recycling modelsTo learn more about the PODD Conference, please visit PODDConference.com.
• 
  Utilizing AI to Facilitate Combination Product Development 05.05.2026 29dk

  In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives discuss specific examples of AI/ML usage by pharma companies through the combination product development process from iteration to commercialization as well as a discussion on how this field will evolve in the coming years.To learn more about the PODD Conference, please visit PODDConference.com.
• 
  Achieving Effective Manufacturing Scaleup for Clinical and Commercial Success 05.05.2026 29dk

  Manufacturing scaleup is a key hurdle in enabling the efficacy of new device technologies. Often this requires a mix of internal and external manufacturing and implementing a commercial control strategy across partners.In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma and CDMO executives discuss effective partnering between pharma and manufacturing as well as growing pains and lessons learned in scaling.To learn more about the PODD Conference, please visit PODDConference.com.
• 
  Advances and Opportunities in Dual Chamber Injectables 05.05.2026 27dk

  In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss progess in the development of liquid/liquid and liquid/lyo dual chamber systems. Specifically, they address: Overcoming primary container and autoinjector challenges for liquid-liquid deliveryImproving upon dual chamber reconstitution devicesFinding the right approach to navigate supply chainTo learn more about the PODD Conference, please visit PODDConference.com.
• 
  How Evinova is Integrating AI into Clinical Development to Bring Big Impact to Big Pharma 24.02.2026 27dk

  About this Podcast: As pharma sponsors continually assesses how to integrate AI into their ways of working, Evinova’s Chief Technology Officer, Sean Connolly, talks about where, how, and when AI is actually making an impact on clinical development based on insights and experiences of working with pharma.Sean share his thoughts on going for low hanging fruit to encourage adoption, what he's seen in terms of pharma companies that are successfully implementing AI across their enterprise, and how he would recommend organizations that are just starting out on their AI journey assess their individual needs and priorities when it comes to AI.More specifically, Sean discusses:  Separating short-term, mid-term and long-term costs and benefits of implementing AI What business leaders at JP Morgan Health 2026 were saying about how they view the value of AI AI deployed for bottom-line revenue versus internal team efficiency What the first steps would be for sponsors to successfully integrate AI across their enterprise 
• 
  How Bayer Reorganized Their Clinical Operations Structure for Efficiency and Cost Savings 29.01.2026 12dk

  About this podcast:Recorded at DPHARM 2025, Bayer's Dr Bernhard Glombitza reports on the development, implementation and early impact of their clinical operations reorgnization. He describes how shifting from a traditional hierarchical model to a network of highly empowered teams reduced management layers, broadening the scope of work and changed cross-country operations monitoring. Dr Glombitza details the results of the change thus far, including significant increases in efficiency and reduction in cost, maintaining quality levels and study targets, and improving employee job satisfaction. 
• 
  How Amicus Embedded Patient Advocacy into its Corporate DNA 29.01.2026 25dk

  About this podcast:In this keynote from Patients as Partners in Clinical Research 2025, Amicus Therapeutics' Chief Patient Advocate, Jayne Gershkowitz, shares how their organization established and embedded patient advocacy into their core structure for lasting impact.More specifically, Ms Gershkowitz focuses on:Defining role standards and recruiting the right talent Co-creatin research with patient communities and developing patient-centered outcomesGenerating metrics that demonstrate the impact on R&D
• 
  Designing Clinical Trials Balancing Simplicity with Complexity 27.01.2026 30dk

  When designing clinical trials, CMOs aim to answer meaningful questions for a plethora of stakeholders. Inherently, this results in study protocols with more measures, biomarkers and data collection that both provides a platform for strategic decision-making but also impacts patient burden, operational foot-print, timelines and cost. In this panel discussion from the 2025 Chief Medical Officer Summit 360°, CMOs address how to develop a balanced strategy that takes into account the ambition to answer these questions with the realities of complicated clinical trials.More specifically:Prioritizing data collection strategy to answer key scientific questions while avoiding overcomplicationDesigning trials around real patients rather than ideal patientsBetter understanding the objectives of the study and asking the questions that achieve those objectivesBetter partnering with patients and PIsTo learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.
• 
  Platform Approaches to Streamline Combination Product Development 27.01.2026 30dk

  Investing in developing a durable platform and strategy early leads to fewer delays throughout development. Locking requirements in early and educating teams to approach combination product development holistically lowers the time to development dramatically. In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss how they used platform devices in concert with an internal engagement strategy to speed up development. Specifically, they address: Advantages and disadvantages to platform approaches for device developmentOpportunities to overcome technical limitationsApproaches to bring a platform into multiple product design history filesRegulatory hurdlesAssessing business case and getting organizational buy-inTo learn more about the PODD Conference, please visit Drug-Delivery.org.